© Odyssey Technologies Limited.
xorkee Handle
Enter your handle to access your profile
Login
In early 2019, the company successfully raised approximately €785,000 to fund this expansion, showing strong investor confidence despite its small-cap status at the time.
The date , fell in the wake of several major corporate actions that reshaped the company's financial health:
In mid-2019, Novacyt’s stock (AIM: NCYT; Euronext Growth: ALNOV) was trading at a fraction of its future value. Share Price | Novacyt novacyy 2019-05-26 SD
Emerging focus on rapid qPCR machines like the genesig® q16 and q32 . 🛠️ Key Strategic Milestones Around May 2019
That same month, Novacyt’s Lab21 unit launched six new products in its PathFlow™ range, targeting pathogens like C. difficile and Norovirus. 📉 Financial Performance and Stock Context In early 2019, the company successfully raised approximately
Novacyt had recently moved to acquire Australian distributor SCD to accelerate its global footprint.
Novacyt (2019-05-26): A Strategic Deep Dive (SD) into a Turning Point 🛠️ Key Strategic Milestones Around May 2019 That
Its molecular diagnostics unit, which was already gaining traction as a partner for clinical assay development.